Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Child Dev. 2019 Nov 25;91(5):1509–1528. doi: 10.1111/cdev.13345

Table 4.

Multilevel Structural Equation Model for GSA Engagement and Anxiety Symptoms

Estimated Paths Coefficient SE 95% CI
GSA Engagement to Wave 2 Mediators
GSA engagement to perceived peer validation 0.208*** 0.043 (0.123, 0.292)
GSA engagement to self-efficacy to promote social justice 0.330*** 0.059 (0.215, 0.446)
GSA engagement to hope 0.235*** 0.076 (0.086, 0.385)
Wave 2 Mediators to Wave 2 Anxiety Symptoms
Perceived peer validation to anxiety symptoms −0.372 0.587 (−1.522, 0.778)
Self-efficacy to promote social justice to anxiety symptoms 0.642 0.523 (−0.383, 1.666)
Hope to anxiety symptoms −3.073*** 0.504 (−4.060, −2.086)
Covariance among Wave 2 Mediators
Peer validation and self-efficacy to promote social justice 0.359*** 0.066 (0.230, 0.488)
Peer validation and hope 0.424*** 0.074 (0.280, 0.569)
Self-efficacy to promote social justice and hope 0.778*** 0.103 (0.577, 0.979)
Autoregressive Associations at Level 1
W1 perceived peer validation to W2 perceived peer validation 0.346*** 0.055 (0.238, 0.454)
W1 self-efficacy to promote social justice to W2 self-efficacy to promote social justice 0.437*** 0.045 (0.349, 0.524)
W1 hope to W2 hope 0.457*** 0.036 (0.386, 0.527)
W1 anxiety symptoms to W2 anxiety symptoms 0.615*** 0.032 (0.553, 0.678)
Demographic Covariates to Wave 2 Anxiety Symptoms
Sexual minority identity to anxiety symptoms (heterosexual as referent) −0.367 1.426 (−3.161, 2.427)
Racial/ethnic minority identity to anxiety symptoms (White as referent) −0.518 1.284 (−3.035, 1.998)
Cisgender male to anxiety symptoms (cisgender female as referent) −3.239* 1.585 (−6.346, −0.132)
Gender expansive to anxiety symptoms (cisgender female as referent) −0.917 1.355 (−3.572, 1.739)
Group-level Predictors to Wave 2 Group-Level Anxiety Symptoms
W1 anxiety symptoms to W2 anxiety symptoms 0.675* 0.288 (0.110, 1.241)
Mental health-related discussions to anxiety symptoms −0.216 0.685 (−1.558, 1.126)
Advisor self-efficacy to address SGM issues to anxiety symptoms 1.115 1.226 (−1.288, 3.518)
Number of GSA meetings to anxiety symptoms −0.252** 0.093 (−0.435, −0.069)

Note. Values are unstandardized coefficient estimates, their standard errors (SE), and 95% confidence intervals (CI). W1 = Wave 1; W2 = Wave 2.

***

p < .001.

**

p < .01.

*

p < .05.